Publication Name	World Journal of Stem Cells
Manuscript ID	57521
Country	Poland

Received	2020-06-12 11:10
Peer-Review Started	2020-06-12 11:11
To Make the First Decision
Return for Revision	2020-07-30 23:32
Revised	2020-08-24 10:12
Second Decision	2020-09-01 11:08
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2020-09-01 20:42
Articles in Press	2020-09-01 20:42
Publication Fee Transferred
Edit the Manuscript by Language Editor	2020-09-06 01:28
Typeset the Manuscript	2020-09-18 17:42
Publish the Manuscript Online	2020-09-22 06:23

ISSN	1948-0210 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Respiratory System
Manuscript Type	Minireviews
Article Title	Perspectives on mesenchymal stem/progenitor cells and their derivates as potential therapies for lung damage caused by COVID-19
Manuscript Source	Invited Manuscript
All Author List	Aleksandra Klimczak
ORCID	Author(s) ORCID Number Aleksandra Klimczak http://orcid.org/0000-0001-6590-4420
Funding Agency and Grant Number
Corresponding Author	Aleksandra Klimczak, DSc, PhD, Full Professor, Laboratory of Biology of Stem and Neoplastic Cells, Hirszfeld Institute of Immunology and Experimental Therapy Polish Academy of Sciences, Rudolfa Weigla 12, Wrocław 53-114, Poland. aleksandra.klimczak@hirszfeld.pl
Key Words	Mesenchymal stem cells; Stem/progenitor cells; Lung damage; Mesenchymal stem cell secretome; COVID-19 disease; COVID-19 pneumonia
Core Tip	The new severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has reached pandemic proportions, developing the coronavirus disease (COVID-19), which leads to the severe pneumonia. The lungs are the primary organ affected by SARS-CoV-2, with a very slow turnover for renewal. SARS-CoV-2 enters the lungs and induces immune response with cytokine storm and subsequent organ dysfunction. To date, there is no effective antiviral therapy for COVID-19. Cell-based therapy involving mesenchymal stem cells (MSCs) and/or their secretome is considered as a supportive therapy for critically ill COVID-19 patients. MSCs can regenerate severely injured respiratory tract cells through their trophic, anti-inflammatory, and immunomodulatory properties.
Publish Date	2020-09-22 06:23
Citation	Klimczak A. Perspectives on mesenchymal stem/progenitor cells and their derivates as potential therapy in lung damage caused by COVID-19. World J Stem Cells 2020; 12(9): 1013-1022
URL	https://www.wjgnet.com/1948-0210/full/v12/i9/1013.htm
DOI	https://dx.doi.org/10.4252/wjsc.v12.i9.1013

Full Article (PDF)	WJSC-12-1013.pdf
Full Article (Word)	WJSC-12-1013.docx
Manuscript File	57521-Review-Filipodia.docx
Answering Reviewers	57521-Answering reviewers.pdf
Audio Core Tip	57521-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	57521-Conflict-of-interest statement.pdf
Copyright License Agreement	57521-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	57521-Language certificate.pdf
Peer-review Report	57521-Peer-review(s).pdf
Scientific Misconduct Check	57521-Scientific misconduct check.pdf
Scientific Editor Work List	57521-Scientific editor work list.pdf
CrossCheck Report	57521-CrossCheck report.pdf